Evidence map›Paper›PMID 33031563›Full record

ArticleArtificial organs2021

Patient-specific in vitro testing for evaluating TAVR clinical performance-A complementary approach to current ISO standard testing.

Brandon J Kovarovic, Oren M Rotman, Puja Parikh, Marvin J Slepian, Danny Bluestein

Open access · greenAbstract read
In one paragraph

Article in Artificial organs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. AI-Powered Multimodal Modeling of Personalized Hemodynamics in Aortic Stenosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Brandon J KovarovicBiofluids Research Group, Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA.ORCID https://orcid.org/0000-0002-3995-8262
Oren M RotmanBiofluids Research Group, Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA.
Puja ParikhDivision of Cardiovascular Medicine, Department of Medicine, Stony Brook University, Stony Brook, NY, USA.
Marvin J SlepianDepartment of Medicine, Sarver Heart Center, University of Arizona, Tucson, AZ, USA.ORCID https://orcid.org/0000-0002-7864-6691
Danny BluesteinBiofluids Research Group, Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA.ORCID https://orcid.org/0000-0002-4014-2308
Stony Brook University · USStony Brook Medicine · USUniversity of Arizona · US

Funding

Biomechanical Approaches and Technologies for Enhancing TAVR OutcomesU01EB026414 · NIBIB · STATE UNIVERSITY NEW YORK STONY BROOK · PI BLUESTEIN, DANNY · 2018 to 2022
$3.8M
A Novel Polymeric Valve for Transcatheter Aortic Valve ReplacementR42HL134418 · NHLBI · POLYNOVA CARDIOVASCULAR, INC · PI BLUESTEIN, DANNY · 2020 to 2022
$2.0M
A Novel Polymeric Valve for Transcatheter Aortic Valve ReplacementR41HL134418 · NHLBI · POLYNOVA CARDIOVASCULAR, INC · PI BLUESTEIN, DANNY · 2017 to 2018
$225k
NHLBI NIH HHS R41 HL134418NHLBI NIH HHS R42 HL134418NHLBI NIH HHS STTR R41-HL134418NIBIB NIH HHS 1U01EB026414-01NIBIB NIH HHS U01 EB026414
6 · The paper itself

Abstract

Following in vitro tests established for surgical prosthetic heart valves, transcatheter aortic valves (TAV) are similarly tested in idealized geometries-excluding effects that may hamper TAVR performance in situ. Testing in vitro in pulse duplicator systems that incorporated patient-specific replicas would enhance the testing veracity by bringing it closer to the clinical scenario. To that end we compare TAV hemodynamic performance tested in idealized geometries according to the ISO standard (baseline performance) to that obtained by testing the TAVs following deployment in patient-specific replicas. Balloon-expandable (n = 2) and self-expandable (n = 3) TAVs were tested in an idealized geometry in mock-circulation system (following ISO 5840-3 guidelines) and compared to the measurements in a dedicated mock-circulation system adapted for the five patient-specific replicas. Patient-specific deployments resulted in a decline in performance as compared to the baseline idealized testing, as well as a variation in performance that depended on the design features of each device that was further correlated with the radial expansion and eccentricity of the deployed TAV stent (obtained with CT-scans of the deployed valves). By excluding the deployment effects in irregular geometries, the current idealized ISO testing is limited to characterize the baseline device performance. Utilizing patient-specific anatomic contours provides performance indicators under more stringent conditions likely encountered in vivo. It has the potential to enhance testing and development complementary to the ISO standard, for improved TAV safety and effectiveness.

Indexed as

Aortic Valve StenosisHumansHydrodynamicsIn Vitro TechniquesModels, CardiovascularPatient SelectionProsthesis DesignProsthesis FailureStentsTomography, X-Ray ComputedTranscatheter Aortic Valve Replacementcalcific aortic valve diseasein vitro hemodynamic testingISO 5840patient-specific testingtranscatheter aortic valve replacement

Identifiers

PMID33031563
PMCPMC8068093
OpenAlexW3092556126

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.